HuaQueJing Medical Secures Tens of Millions RMB in Series A Funding Led by Shenzhen Capital Group to Advance Intelligent Rehabilitation Robotics

At the Start of the New Year, the Rehabilitation Robotics Sector Welcomes Major Financing News.

VCBeat has learned that an internationally leading rehabilitation robotics company,Shenzhen Huaquejing Medical Technology Co., Ltd.(abbreviated as"Hua Quejing Medical") announced that it has recently completed a tens-of-millions-of-RMB Series A financing round, exclusively invested by SCGC. The funds raised will be used to scale up product mass production, advance marketing and brand building, and continuously consolidate the company’s technological leadership in its products, all in alignment with its vision and mission.

Hua Quejing Medical, established in July 2019 and headquartered in Shenzhen, is an innovative technology enterprise dedicated to intelligent rehabilitation robots and comprehensive smart rehabilitation medical solutions. Leveraging the founding team’s over 15 years of R&D experience and robust technical accumulation in rehabilitation medicine, medical robotics, artificial intelligence, and virtual reality, Hua Quejing Medical was recognized as a National High-Tech Enterprise within three years of its establishment. The company has completed the development of multiple intelligent rehabilitation robots for the upper limbs, fingers, cognition, speech, and spine, with several products having obtained NMPA medical device registration certificates. It holds more than 70 intellectual property rights, including domestic and international invention patents.

Hua Quejing Medical’s self-developed intelligent rehabilitation products have also received numerous honors, including the First Prize from the Chinese Association of Rehabilitation Medicine, the Second Prize for Science and Technology from the China Association of Acupuncture-Moxibustion, the First Prize for Science and Technology from the Guangdong Provincial Association of Acupuncture-Moxibustion, and recognition as a Guangdong Provincial Premium High-Tech Product.

Leveraging its independently developed, unified hardware-software architecture for rehabilitation robotics, along with technologies such as robotic control algorithms, human-computer interaction, intelligent assessment, bionic exoskeleton design, soft robotics, virtual reality, and sensors, Hua Quejing Medical has developed a series of innovative intelligent rehabilitation robots and equipment, establishing a multi-tiered product portfolio.

It offers not only rehabilitation products tailored for hospital specialties but also those designed for community and home-based rehabilitation, thereby forming a full-cycle, systematic, and intelligent rehabilitation solution that addresses the needs of diverse scenarios. This solution establishes a collaborative relationship among patients, therapists, and robots, enabling efficient interaction and emotional integration.

Hua Quejing Medical Provides Full-Cycle, Systematic, and Intelligent Rehabilitation Solutions

Wisebot^®X5 is based onNeuroplasticityHua Quejing Medical has innovatively proposed an exoskeleton rehabilitation robot meticulously designed for stroke patients with hemiplegia, based on rehabilitation theories such as mirror neurons.Intelligent assessment technology for Brunnstrom staging and range of motion, as well as deep learning-based intelligent rehabilitation training program generation technology.

Wisebot^®X5 simulates the movement patterns of the human upper limb in real time across multiple dimensions, providing active, passive, and active-passive training modes to meet the rehabilitation needs of different stages.Pioneered a mirror training mode, enabling patients to independently determine training movements for the affected side and achieving coordinated synchronous training of both the healthy and affected sides., significantly enhancing the effectiveness and efficiency of rehabilitation.

Wisebot^®In addition to significantly enhancing patients' autonomy and confidence in rehabilitation, the mirror training mode of X5 facilitates interaction between the unaffected hemisphere and the injured brain, reduces interhemispheric inhibition, increases activation levels in functional cortical areas, and expands the extent of activated regions. This more effectively promotes neuroplastic changes and functional reorganization, thereby facilitating functional recovery in the damaged areas.

Wisebot^®The X5 not only demonstrates the core technological capabilities of Hua Quejing Medical, but also represents the evolutionary direction of next-generation rehabilitation robots from both clinical and technical perspectives. It marks another breakthrough in key core technologies within China’s rehabilitation robotics sector, fills an international gap in this field, and provides innovative intelligent neurological rehabilitation solutions for hemiplegic patients worldwide.

Hua Quejing Medical’s ability to efficiently translate clinical needs and urgent pain points into engineering language, deeply integrate clinical practice, technology, and product development, and launch internationally pioneering products with independent core intellectual property rights is attributable to its strong multidisciplinary R&D team specializing in the intersection of medicine and engineering.

The company’s R&D team comprises top-tier experts in rehabilitation medicine and robotics, including academicians, recipients of the National Science Fund for Distinguished Young Scholars, and professors from prestigious institutions such as the Chinese Academy of Sciences (CAS) and Harbin Institute of Technology. Dr. Wu Jianhuang, a co-founder, is a researcher at CAS and a doctoral supervisor. With nearly two decades of experience in surgical robotics, computer-assisted medicine, and translational medicine, he has led approximately 20 national, provincial, and municipal science and technology programs and spearheaded the development of systems such as vascular interventional surgical robots. The other co-founders include senior leaders from rehabilitation industry associations, seasoned experts with long-term involvement in medical robot research and development from the State Key Laboratory of Robotics, sales and product directors from renowned medical device groups, and business elites who have achieved remarkable industry performance and accumulated extensive upstream and downstream resources.

On the other hand, Hua Quejing Medical has adhered to the R&D logic of “derived from clinical practice, applied back to clinical practice” since its inception. The company has maintained in-depth exchanges and fostered industry-academia-research collaboration with the scientific research and clinical team led by Academician Chen Lidian, President of the Chinese Association of Rehabilitation Medicine and Director of the National-Local Joint Engineering Research Center for Rehabilitation Medical Technology. By continuously iterating its products based on rigid clinical needs, pain points, and feedback, Hua Quejing ensures that its offerings deliver high-quality services to patients, physicians, and healthcare institutions.

Accelerating population aging is awakening demand, with rehabilitation needs continuing to grow; rehabilitation has become a key public livelihood issue. According to Frost & Sullivan projections, the market size of China’s rehabilitation medical device industry will grow at a compound annual growth rate (CAGR) of approximately 20%, exceeding RMB 100 billion by 2025.

From a policy perspective, China has incorporated rehabilitation into its national development strategy, emphasizing the importance and urgency of advancing rehabilitation medicine through top-level design. The National "14th Five-Year Plan" for the Development of the Medical Equipment Industry explicitly identifies intelligent rehabilitation robots and exoskeleton rehabilitation robots as key areas for technological breakthroughs. Similarly, the "14th Five-Year Plan" for National Health clearly prioritizes the development of new health products, such as intelligent rehabilitation assistive devices.

Amidst the confluence of rising market demand, supportive policies, rapid scale-up, empowerment by leading capital, and strong in-house R&D capabilities, Hua Quejing Medical has embarked on a new journey, entering a period of explosive commercial growth.

For this round of financing,Dr. Wu Jianhuang, CEO of Hua Quejing MedicalThe statement read: “We are deeply grateful to SCGC for its recognition and support of Huaquejing Medical’s innovation and industrialization capabilities. We also extend our special thanks to Professor Wang Tianmiao’s team, our investors from the previous round, for their unwavering support, and to all Huaquejing Medical employees for their steadfast commitment and persistent pursuit of the company’s mission and vision. Since its inception, Huaquejing Medical has upheld the mission of ‘helping people achieve health and happiness.’ Leveraging the founding team’s over 15 years of technical accumulation and R&D experience in the field of medical-engineering crossover products, we will continue to develop innovative solutions that address rigid clinical needs and pain points in rehabilitation. Our goal is to alleviate the burden on therapists, enhance rehabilitation efficiency, enable more patients to access intelligent rehabilitation services, and help them return to society sooner and improve their quality of life. Huaquejing Medical will always remain patient-centric, create value for clinical practice, and relentlessly pursue innovation in technology, products, and services. We will actively respond to the national call for the domestication of high-end medical devices and strive to become a world-class medical technology company with lasting impact.”

SCGC Investment TeamIt stated: “The Report to the 20th National Congress of the Communist Party of China explicitly emphasized prioritizing the protection of people’s health in strategic development and implementing a national strategy to proactively address population aging. Rehabilitation medicine has long been a key area of focus for SCGC (Shenzhen Capital Group). As a leading domestic developer of intelligent rehabilitation robots, Hua Quejing Medical boasts a founding team with profound expertise in both medicine and engineering, offering deep insights into industry trends and clinical needs. By deeply integrating clinical rehabilitation requirements, advanced rehabilitation theories, and AI-driven robotic technologies, the company has creatively developed multiple globally leading products that deliver precise, intelligent, and high-quality services to patients. We are delighted to see that Hua Quejing Medical’s products have not only improved rehabilitation outcomes and efficiency but also enhanced patients’ quality of life. We are pleased to collaborate with such a highly creative and efficiently executing team as Hua Quejing Medical. Leveraging SCGC’s accumulated industry experience and resources, we will continue to deepen our cooperation with Hua Quejing Medical across multiple dimensions, providing comprehensive support to deliver more high-value products and services to patients and the general public. Together, we aim to promote the development of China’s intelligent rehabilitation sector and contribute to the Healthy China initiative.”

Shenzhen Capital Group Co., Ltd. (hereinafter referred to as “SCGC”) was established in 1999 with capital contributed by the Shenzhen Municipal Government and guided social capital. With the mission of discovering and empowering great enterprises, SCGC is committed to being a discoverer and cultivator of innovative value. It has developed into a comprehensive investment group centered on venture capital, with a registered capital of RMB 10 billion and total assets under management of approximately RMB 433.4 billion. Adhering to the philosophy of “30% investment, 70% services,” the company promotes the rapid and healthy development of its portfolio companies through resource integration, capital operations, regulatory oversight, and training and mentorship. As of December 2022, SCGC led the industry in the number of portfolio companies listed, with 239 investee companies listed across 17 capital markets worldwide. Due to its outstanding performance in the venture capital sector, SCGC has consistently ranked among the top in comprehensive rankings of venture capital firms conducted by authoritative institutions such as the China Venture Capital and Private Equity Association, Zero2IPO Group, and CVSource. From 2016 to 2022, SCGC ranked first among domestic venture capital firms in Zero2IPO’s Annual Ranking of Chinese Venture Capital Institutions.

Recommended Reading: “Providing Full-Cycle Solutions to Facilitate the Decentralization of Rehabilitation Services, Hua Quejing Leads in Smart Neurorehabilitation Robotics”